Search

Your search keyword '"Hevia, Vital"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Hevia, Vital" Remove constraint Author: "Hevia, Vital" Database Unpaywall Remove constraint Database: Unpaywall
40 results on '"Hevia, Vital"'

Search Results

1. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy

2. CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS RECEIVING TKI THERAPY VERSUS IMMUNE CHECKPOINT INHIBITOR THERAPY: ANALYSIS OF THE REMARCC REGISTRY

5. Effectiveness of endourological management of ureteral stenosis in kidney transplant patients: EAU-YAU kidney transplantation working group collaboration

7. PD31-03 EFFECTIVENESS OF ENDOUROLOGICAL MANAGEMENT OF URETERAL STENOSIS IN KIDNEY TRANSPLANT PATIENTS: EAU-YAU KIDNEY TRANSPLANTATION WORKING GROUP COLLABORATION

8. Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 (“Oligometastatic”) and M2 (“Polymetastatic”) subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)

10. Urologists and Kidney Transplantation: The First European Census

12. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry

15. PD18-01 CYTOREDUCTIVE NEPHRECTOMY IN PATIENTS RECEIVING TKI THERAPY VERSUS IMMUNE CHECKPOINT INHIBITOR THERAPY: ANALYSIS OF THE REMARCC REGISTRY

16. Corrigendum to ‘Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)’ [European Urology Oncology 3 (2021) 256–263]

17. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)

18. What Should Be Known by a Urologist About the Medical Management of COVID-19’s Patients?

19. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma

20. MP14-07 PERFORMANCE OF A NEW RISK ASSESSMENT TOOL FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA UNDERGOING CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: REMARCC SCORE

21. Does presence of bone metastases portend worsened prognosis in metastatic renal cell carcinoma? Analysis of the REMARCC (Registry of MetAstatic RCC) database.

25. Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review

26. MP25-12 PREDICTORS OF MAJOR COMPLICATIONS AFTER CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA: INSIGHTS FROM A RETROSPECTIVE MULTICENTRE REGISTRY

29. Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel

32. The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review

34. MP06-20 RANDOMIZED EXPERIMENTAL STUDY COMPARING NON-OXYGENATED VS OXYGENATED HYPOTHERMIC MACHINE PERFUSION IN A TYPE III NON-HEART-BEATING DONOR PIG MODEL OF AUTOTRANSPLANTATION.

38. Contrast-Enhanced Ultrasound (CEUS): an Excellent Tool in the Follow-up of Small Renal Masses Treated with Cryoablation

Catalog

Books, media, physical & digital resources